Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 7.54
PRTA's Cash-to-Debt is ranked lower than
59% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. PRTA: 7.54 )
Ranked among companies with meaningful Cash-to-Debt only.
PRTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.54  Med: No Debt Max: No Debt
Current: 7.54
Equity-to-Asset 0.79
PRTA's Equity-to-Asset is ranked higher than
65% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PRTA: 0.79 )
Ranked among companies with meaningful Equity-to-Asset only.
PRTA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.78  Med: 0.94 Max: 0.98
Current: 0.79
-1.78
0.98
Piotroski F-Score: 1
Altman Z-Score: 12.32
Beneish M-Score: -3.76
WACC vs ROIC
21.42%
-1196.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -15121.80
PRTA's Operating Margin % is ranked lower than
94% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. PRTA: -15121.80 )
Ranked among companies with meaningful Operating Margin % only.
PRTA' s Operating Margin % Range Over the Past 10 Years
Min: -15121.8  Med: -4974.3 Max: -13.07
Current: -15121.8
-15121.8
-13.07
Net Margin % -15176.11
PRTA's Net Margin % is ranked lower than
94% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. PRTA: -15176.11 )
Ranked among companies with meaningful Net Margin % only.
PRTA' s Net Margin % Range Over the Past 10 Years
Min: -15176.11  Med: -5016.3 Max: -14.06
Current: -15176.11
-15176.11
-14.06
ROE % -39.56
PRTA's ROE % is ranked lower than
53% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. PRTA: -39.56 )
Ranked among companies with meaningful ROE % only.
PRTA' s ROE % Range Over the Past 10 Years
Min: -68.99  Med: -27.35 Max: -3.09
Current: -39.56
-68.99
-3.09
ROA % -34.53
PRTA's ROA % is ranked lower than
54% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. PRTA: -34.53 )
Ranked among companies with meaningful ROA % only.
PRTA' s ROA % Range Over the Past 10 Years
Min: -1640.13  Med: -32.1 Max: -2.94
Current: -34.53
-1640.13
-2.94
ROC (Joel Greenblatt) % -505.41
PRTA's ROC (Joel Greenblatt) % is ranked lower than
52% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. PRTA: -505.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2303.58  Med: -1285.66 Max: -204.81
Current: -505.41
-2303.58
-204.81
3-Year Revenue Growth Rate -4.90
PRTA's 3-Year Revenue Growth Rate is ranked lower than
63% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. PRTA: -4.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRTA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: -15.05 Max: 289
Current: -4.9
-33.7
289
3-Year EBITDA Growth Rate 28.90
PRTA's 3-Year EBITDA Growth Rate is ranked higher than
81% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. PRTA: 28.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRTA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.7  Med: 13.25 Max: 37.3
Current: 28.9
-50.7
37.3
3-Year EPS without NRI Growth Rate 28.40
PRTA's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PRTA: 28.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRTA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.9  Med: 13.1 Max: 36.8
Current: 28.4
-47.9
36.8
GuruFocus has detected 4 Warning Signs with Prothena Corp PLC $PRTA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRTA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PRTA Guru Trades in Q1 2016

Vanguard Health Care Fund 2,150,294 sh (+29.32%)
Ken Fisher 19,076 sh (+0.19%)
Jim Simons Sold Out
» More
Q2 2016

PRTA Guru Trades in Q2 2016

Pioneer Investments 119,958 sh (New)
Vanguard Health Care Fund 2,150,294 sh (unchged)
Ken Fisher 19,040 sh (-0.19%)
» More
Q3 2016

PRTA Guru Trades in Q3 2016

Vanguard Health Care Fund 2,150,294 sh (unchged)
Pioneer Investments 119,324 sh (-0.53%)
Ken Fisher 13,856 sh (-27.23%)
» More
Q4 2016

PRTA Guru Trades in Q4 2016

Vanguard Health Care Fund 2,150,294 sh (unchged)
Pioneer Investments 116,424 sh (-2.43%)
Ken Fisher 10,718 sh (-22.65%)
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TBPH, OTCPK:ABCZF, NAS:AVXS, NYSE:CBM, NAS:LGND, NAS:PTLA, OTCPK:VNAPF, NAS:AAAP, NAS:DBVT, OTCPK:MPSYY, NAS:HALO, NAS:JUNO, NYSE:XON, NAS:ONCE, OTCPK:BVNRY, NAS:SRPT, NAS:GBT, NAS:FGEN, NAS:AGIO, NAS:ARRY » details
Traded in other countries:0PT.Germany,
Headquarter Location:Ireland
Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.

Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.

Top Ranked Articles about Prothena Corp PLC

Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease
Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson’s Disease to be Presented at the 13th​ International Conference on Alzheimer's and Parkinson's Diseases
Investor webcast planned for April 2, 2017 at 9:00 AM EDT to discuss Phase 1b study results  Prothena and Roche to co-host symposium on alpha-synuclein pathology and non-motor manifestations in Parkinson’s disease on March 31, 2017 at 5:15 CET DUBLIN, Ireland, March 09, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from the Phase 1b multiple ascending dose study of PRX002 in patients with Parkinson’s disease will be highlighted in an oral presentation in the late-breaking therapeutic strategies session at the 13th ​International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), to be held March 29 – April 2, in Vienna, Austria. PRX002, also known as RG7935, is a monoclonal antibody for the potential treatment of Parkinson's disease and other related synucleinopathies, and is the focus of a worldwide collaboration between Prothena and Roche. A Phase 2 clinical study of PRX002/RG7935 in patients with Parkinson's disease is expected to begin in 2017.
Clinical data from the Phase 1b multiple ascending dose study of PRX002/RG7935 in patients with Parkinson’s disease, will be presented in the following oral session:Results from a Phase 1b Multiple Ascending-dose Study of PRX002/RG7925, An Anti-alpha-synuclein Monoclonal Antibody, in Patients with Parkinson’s DiseasePresenter: Joseph Jankovic, MD, Distinguished Chair in Movement Disorders, Baylor College of MedicineSession: Symposium 58 – Late Breaking Therapeutic Strategies in AD and PDDate and Time: Oral presentation – Sunday, April, 2, 12:00 – 12:15 PM CET (6:00 – 6:15 AM EDT)Location: Hall C, Austria Center, Vienna, AustriaAn investor conference call and webcast to discuss the results is planned for Sunday, April 2, 2017 at 9:00 AM  EDT, and dial-in details will be made available in advance of the call.In addition, an abstract on the feasibility of using smartphone-based assessments and sensors to monitor symptoms and mobility in patients with early-stage Parkinson’s disease will be presented in the following oral presentation:Remote, High-frequency Monitoring of Motor Symptoms in Early-stage Parkinson’s Disease Patients in the Phase 1b RG7935/PRX002 Clinical TrialPresenter: Michael Lindemann, Professor, Baden-Württemberg Cooperative State UniversitySession: Symposium 58 – Late Breaking Therapeutic Strategies in AD and PDDate and Time: Oral presentation – Sunday, April, 2, 12:15 – 12:30 PM CET (6:15 – 6:30 AM EDT)Location: Hall C, Austria Center, Vienna, AustriaProthena and Roche to Co-Host Symposium In addition to the scientific presentation, leading researchers in the field of Parkinson's disease will present at a symposium entitled “Beyond the Basal Ganglia: Alpha-synuclein Pathology and Non-motor Manifestations in Parkinson’s Disease” during the conference. The symposium will be held on March 31, 2017 at 5:15 PM local time, and will feature experts from around the world, including: Thomas Beach, MD, PhD, Sun Health Research Institute, Sun City; Patrik Brundin, MD, PhD, Van Andel Research Institute, Grand Rapids; Jamie L Eberling, PhD, The Michael J. Fox Foundation for Parkinson’s Research, New York; Tom Isaacs, The Cure Parkinson’s Trust, Rickmansworth, Herts; Brit Mollenhauer, MD, Georg-August University Göttingen, Göttingen; Wolfgang Oertel, MD, PhD, of University of Marburg, Marburg; Ronald Postuma, MD, MSc, McGill University, Montreal.
About Alpha-synucleinAlpha-synuclein, a protein found in neurons and other cells, is a major component of pathology that characterizes several neurodegenerative disorders including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, which collectively are termed synucleinopathies. While the normal function of alpha-synuclein is not well understood, the protein generally occurs in a soluble form. In synucleinopathies, the alpha-synuclein protein can misfold and aggregate to form soluble aggregates and insoluble fibrils that contribute to disease pathology. There is increasing evidence that this disease-causing alpha-synuclein can be propagated and transmitted from neuron to neuron, resulting in an infection-like spread of neuronal death. Recent studies in cellular and animal models suggest that the spread of alpha-synuclein-associated neurodegeneration can be disrupted by targeting aberrant forms of alpha-synuclein.
About PRX002/RG7935PRX002/RG7935 is a monoclonal antibody under development for the potential treatment of Parkinson's disease. PRX002/RG7935 targets alpha-synuclein and is designed to slow the progressive neurodegeneration associated with alpha-synuclein misfolding and/or the cell-to-cell transmission of the aggregated pathogenic forms of alpha-synuclein found in Parkinson's disease and other synucleinopathies. Prior to initiating clinical trials, Prothena demonstrated the efficacy of PRX002/RG7935 in various cellular and animal models of alpha-synuclein-related disease. In multiple transgenic mouse models of Parkinson's disease, the murine version of PRX002/RG7935, reduced the appearance of alpha-synuclein pathology, protected synapses and improved performance in behavioral testing. In December 2013 Prothena and Roche entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002/RG7935. Prothena has an option to co-promote PRX002/RG7935 in the U.S., where the companies share all development and commercialization costs, as well as profits, on a 30/70 basis (30 percent Prothena, 70 percent Roche). Outside the U.S., Roche will have sole responsibility for developing and commercializing PRX002/RG7935 and will pay Prothena up to double-digit royalties on net sales. A Phase 2 clinical study of PRX002/RG7935 in patients with Parkinson's disease is expected to begin in 2017.
About Parkinson's DiseaseParkinson's disease is a progressive degenerative disorder of the central nervous system (CNS) that affects one in 100 people over age 60. With an estimated seven to 10 million patients living with Parkinson's disease worldwide, it is the second most common neurodegenerative disorder after Alzheimer's disease. The disease is characterized by the neuronal accumulation of aggregated alpha-synuclein in the CNS and peripheral nervous system that results in a wide spectrum of worsening progressive motor and non-motor symptoms. While diagnosis relies on motor symptoms classically associated with Parkinson's disease, non-motor symptoms may present many years earlier. Current treatments for Parkinson's disease are symptomatic and only address a subset of symptoms such as motor impairment, dementia, or psychosis. Symptomatic therapies do not target the underlying cause of the disease and lose effectiveness, often leading to debilitating side effects as the disease progresses.
About ProthenaProthena Corporation plc is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena seeks to fundamentally change the course of progressive diseases associated with this biology. The Company’s pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002/RG7935), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The company continues discovery of additional novel therapeutic candidates where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the company's website at www.prothena.com. Forward-looking Statements This press release contains forward-looking statements. These statements relate to, among other things, plans for and the timing of initiating a Phase 2 clinical study of PRX002/RG7935; and the design of PRX002/RG7935 and its potential as a disease modifying treatment for Parkinson's disease. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks, uncertainties and other factors described in the "Risk Factors" sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2017 filed with the SEC. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena's expectations.
Contacts:

Investors: Tran Nguyen, CFO
650-837-8535, [email protected]

Media: Ellen Rose, Head of Communications
650-922-2405, [email protected]

Read more...
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares

DUBLIN, Ireland, March 03, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has sold 2,700,000 of its ordinary shares at a price to the public of $57.50 per ordinary share. Gross proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $155.3 million, before deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriter's option to purchase additional ordinary shares. The offering is expected to close on March 8, 2017, subject to customary closing conditions. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriter a 30-day option to purchase up to an additional 405,000 of its ordinary shares.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for the offering. The ordinary shares of Prothena described above were offered only by means of a prospectus supplement and base prospectus forming part of an effective shelf registration statement filed with the Securities and Exchange Commission. Copies of the prospectus for this offering may be obtained, when available, by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th Floor, New York, New York 10022, or by telephone at 212-829-7122, or by e-mail at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Prothena Prothena Corporation plc is a global, late-stage clinical biotechnology company with a clinical pipeline of novel therapeutic antibodies. Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). Forward-Looking Statements This press release contains forward-looking statements. These statements relate to, among other things, the timing and size of the proposed offering, the conditions affecting the capital markets, general economic, industry, or political conditions, and the satisfaction of customary closing conditions related to the proposed offering. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks, uncertainties and other factors described in the “Risk Factors” sections of Prothena’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2017 and in the preliminary prospectus supplement related to the offering filed with the SEC on March 2, 2017. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena’s expectations.
Contact
Investors: Tran Nguyen, CFO
650-837-8535, [email protected]

Media: Ellen Rose, Head of Communications
650-922-2405, [email protected]

Read more...
Prothena Announces Public Offering of Ordinary Shares

DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has commenced a registered underwritten public offering of 2,700,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena.  In addition, Prothena has granted the underwriter a 30-day option to purchase up to an additional 405,000 of its ordinary shares.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for the offering. The ordinary shares of Prothena described above are being offered only by means of a prospectus supplement and base prospectus forming part of an effective shelf registration statement filed with the Securities and Exchange Commission. Copies of the prospectus for this offering may be obtained, when available, by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th Floor, New York, New York 10022, or by telephone at 212-829-7122, or by e-mail at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Prothena Prothena Corporation plc is a global, late-stage clinical biotechnology company with a clinical pipeline of novel therapeutic antibodies. Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). Forward-Looking Statements This press release contains forward-looking statements. These statements relate to, among other things, the timing and size of the proposed offering, the conditions affecting the capital markets, general economic, industry, or political conditions, and the satisfaction of customary closing conditions related to the proposed offering. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks, uncertainties and other factors described in the "Risk Factors" sections of Prothena’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2017 and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena's expectations.
Contact
Investors: Tran Nguyen, CFO
650-837-8535, [email protected]

Media: Ellen Rose, Head of Communications
650-922-2405, [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 5.17
PRTA's PB Ratio is ranked lower than
65% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. PRTA: 5.17 )
Ranked among companies with meaningful PB Ratio only.
PRTA' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.43 Max: 6.28
Current: 5.17
0.84
6.28
PS Ratio 1770.64
PRTA's PS Ratio is ranked lower than
98% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. PRTA: 1770.64 )
Ranked among companies with meaningful PS Ratio only.
PRTA' s PS Ratio Range Over the Past 10 Years
Min: 8.25  Med: 309.58 Max: 1800.32
Current: 1770.64
8.25
1800.32
EV-to-EBIT -11.64
PRTA's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. PRTA: -11.64 )
Ranked among companies with meaningful EV-to-EBIT only.
PRTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -348.9  Med: -12 Max: 0.9
Current: -11.64
-348.9
0.9
EV-to-EBITDA -11.82
PRTA's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. PRTA: -11.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -103.1  Med: -10.6 Max: 4476
Current: -11.82
-103.1
4476
Current Ratio 9.53
PRTA's Current Ratio is ranked higher than
77% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. PRTA: 9.53 )
Ranked among companies with meaningful Current Ratio only.
PRTA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 20.53 Max: 72.16
Current: 9.53
0.01
72.16
Quick Ratio 9.53
PRTA's Quick Ratio is ranked higher than
77% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. PRTA: 9.53 )
Ranked among companies with meaningful Quick Ratio only.
PRTA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 20.53 Max: 72.16
Current: 9.53
0.01
72.16
Days Sales Outstanding 61.58
PRTA's Days Sales Outstanding is ranked higher than
50% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. PRTA: 61.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.41  Med: 31.32 Max: 115.61
Current: 61.58
12.41
115.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
PRTA's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. PRTA: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.6  Med: -18.95 Max: -14.7
Current: -16.4
-23.6
-14.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.47
PRTA's Price-to-Net-Cash is ranked higher than
50% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. PRTA: 6.47 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PRTA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.06  Med: 3.46 Max: 6.51
Current: 6.47
1.06
6.51
Price-to-Net-Current-Asset-Value 6.38
PRTA's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. PRTA: 6.38 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PRTA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.05  Med: 3.43 Max: 6.41
Current: 6.38
1.05
6.41
Price-to-Tangible-Book 5.18
PRTA's Price-to-Tangible-Book is ranked lower than
57% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. PRTA: 5.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PRTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.02  Med: 3.35 Max: 5.99
Current: 5.18
1.02
5.99
Price-to-Median-PS-Value 5.72
PRTA's Price-to-Median-PS-Value is ranked lower than
96% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. PRTA: 5.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRTA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 2.26 Max: 5.75
Current: 5.72
0.03
5.75
Earnings Yield (Greenblatt) % -8.59
PRTA's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. PRTA: -8.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRTA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.96  Med: 155.6 Max: 74709.2
Current: -8.59
-8.96
74709.2

More Statistics

Revenue (TTM) (Mil) $1.06
EPS (TTM) $ -4.66
Beta3.49
Short Percentage of Float29.44%
52-Week Range $33.53 - 68.18
Shares Outstanding (Mil)37.94

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 25 36 21
EPS ($) -3.90 -2.77 -5.09
EPS without NRI ($) -3.90 -2.77 -5.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Apr 02 2017 
Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Mar 09 2017 
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares Mar 03 2017 
Prothena Announces Public Offering of Ordinary Shares Mar 02 2017 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) Profita Mar 20 2015 
Three Stocks With Massive Insider Buying Sep 03 2014 

More From Other Websites
Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : April 24, 2017 Apr 24 2017
Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : April 21, 2017 Apr 21 2017
Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : April 6, 2017 Apr 06 2017
Prothena Corporation plc : Press Release Apr 02 2017
Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust... Apr 02 2017
Don't Let Offerings Blindside Your Thesis Mar 19 2017
Why Is Prothena (PRTA) Up 4.5% Since the Last Earnings Report? Mar 17 2017
Results for Prothena's Phase 1b Multiple Ascending Dose Study of PRX002... Mar 09 2017
Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with... Mar 09 2017
Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market Mar 03 2017
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares Mar 03 2017
Prothena Corporation plc : Prothena Announces Public Offering of Ordinary Shares Mar 02 2017
Prothena Announces Public Offering of Ordinary Shares Mar 02 2017
Prothena Corp. Plc :PRTA-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017 Feb 17 2017
Prothena (PRTA) Reports Wider-than-Expected Loss in Q4 Feb 15 2017
Edited Transcript of PRTA earnings conference call or presentation 14-Feb-17 9:30pm GMT Feb 15 2017
Prothena reports 4Q loss Feb 14 2017
Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial... Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)